Blockchain

Cartesi and Avail Announce Strategic Integration to Advance Web3 Development

New York, New York, July 2nd, 2024, Chainwire

Cartesi, a modular execution layer protocol that equips developers with access to a full Linux environment, and Avail, a modular blockchain framework designed to unify web3 and optimize data availability (DA) for scalable and customizable applications, are pleased to announce a close collaboration set to significantly advance web3 development.

This integration will offer a seamless and intuitive experience for developers by leveraging Cartesi’s RISC-V Linux-based execution capabilities and Avail’s reliable data availability solution, Avail DA. The user-friendly approach will simplify the complexities of decentralized application development, enabling faster and more efficient project deployment.

The modular stack allows both protocols to combine their unique properties, resulting in a robust protocol that is more powerful compared to monolithic stacks where all functionalities are integrated. In this sense, the Cartesi-Avail integration will enable developers to benefit from the increased computational power and flexible programming environment of the Cartesi stack, while also utilizing the enhanced data availability capabilities of Avail DA.

“By combining Cartesi’s cutting-edge RISC-V Linux-based execution with Avail DA, we are setting a new standard in the ease and efficiency of protocol development. This partnership empowers developers to overcome traditional barriers, accelerating innovation and the deployment of next-generation decentralized applications. We are thrilled to enable this leap forward in web3 development,” said Anurag Arjun, Co-Founder of Avail.

The collaboration between Cartesi and Avail marks a significant milestone in the web3 space. A dedicated data availability layer ensures critical transaction data remains available and verifiable while significantly reducing the costs associated with on-chain data availability. This makes dApps more affordable and accessible, while reliable data availability is crucial for the execution layer to perform transactions and execute contracts seamlessly. 

“The Cartesi-Avail integration brings into reality a powerful infrastructure for new possibilities and use cases in web3. This is exciting for us and a breath of fresh air for the industry,” said Erick de Moura, Co-Founder of Cartesi.

This partnership is expected to drive the creation of a more robust and versatile ecosystem, particularly benefiting gaming and DeFi verticals, empowering developers to experiment and innovate without being hindered by the limitations of current infrastructure.

Cartesi equips developers with access to a full Linux environment through its native virtual machine, and high-performance rollups designed to support next-generation dApps. By bridging the gap between traditional software and blockchain, Cartesi enables developers to create more sophisticated and scalable dApps with ease. Avail DA offers secure data availability guarantees for entire networks of blockchains, enabling them to scale efficiently and in an unlimited capacity. Using validity proofs with data availability sampling provides robust security and enhanced scalability for blockchain applications. 

About Cartesi: 

Cartesi is a powerful modular blockchain protocol that supercharges the web3 space. Cartesi equips developers with access to a full Linux environment through its native virtual machine, and high-performance rollups designed to support next-generation dApps. To learn more about Cartesi, users can visit https://cartesi.io/

About Avail:

Avail is led by Polygon’s former co-founder Anurag Arjun and is building a unification layer to solve rollup fragmentation at scale. Avail addresses this from first principles solving blockchain scalability with Avail DA, a foundational DA layer which implements the same technology planned for Ethereum’s danksharding roadmap, including KZG Commitments and Data Availability Sampling (DAS). Avail Nexus addresses growing fragmentation concerns with permissionless interoperability, leveraging proof aggregation on Avail’s scalable DA layer. Avail’s security is then reinforced with multi-asset staking through Avail Fusion.

availproject.org

Users can learn more about Avail on Discord, Twitter, GitHub, Our Blog

Contact

PR Manager
Lindsay Strebel
Blokhaus Inc.
[email protected]

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Keiretsu Forum Announces Dr. Martin Gershon as Keynote Speaker for 2024 Investor Capital Expo

2024-10-02T11:08:00Z

PHILADELPHIA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum, the world's largest and most active accredited angel investor network, is proud to announce that Dr. Martin Gershon, a prominent leader in healthcare innovation and venture capital, will deliver the keynote address at the 2024 Investor Capital Expo. This signature event in early-stage investment community will be held on October 31, 2024, at Convene City View in Philadelphia.

Dr. Gershon, Managing Partner and Chief Investment Officer of Endeavor Venture Funds and Endeavor Venture Studio, brings over two decades of experience in life sciences and healthcare startups. His leadership at Endeavor has resulted in over 100 investments and 24 successful exits, solidifying his reputation as a strategic force in healthcare investment. Under his guidance, Endeavor Venture Funds has become synonymous with cutting-edge innovation, most recently, in artificial intelligence (AI)-powered drug discovery.

Recognized as a "Top Voice" in Venture Capital and Entrepreneurship by LinkedIn and named a Top 100 Healthcare Industry Leader by Standard & Poor’s, Dr. Gershon is a sought-after advisor and speaker. His keynote, titled "Pioneering Healthcare Innovation: Investment Strategies in AI Drug Discovery," will delve into the transformative impact of AI on the drug development process. His address will focus on:

  • Investment Opportunities: Exploring high-growth potential in AI-driven drug discovery.
  • Strategic Insights: Understanding how AI is accelerating the development of novel therapeutics.
  • Future Trends: Highlighting upcoming innovations that will shape the life sciences and healthcare sectors.

Keiretsu Forum: A Global Leader in Early-Stage Innovation

Keiretsu Forum continues to be a global leader in early-stage innovation, offering unparalleled access to groundbreaking companies across industries. The Investor Capital Expo serves as the premier gathering for angel investors, venture capitalists, family offices, and entrepreneurs, spotlighting companies that have undergone Keiretsu Forum's rigorous due diligence process. The event provides an invaluable platform for investors to engage with high-potential startups, network with peers, and gain insights from leading industry experts.

Keiretsu Forum has a relationship with Endeavor and Dr Gershon that has at its core aligned vision and lays the solid platform for access to a larger number of remarkable Founder Entrepreneurs and strategic partnerships with the Endeavor investor ecosystem for follow on rounds and sustained growth.

"Dr. Gershon's expertise in healthcare and AI makes him an ideal keynote speaker for this year’s Expo," said Howard Lubert, Regional President of Keiretsu Forum. "His contributions to the commercialization of life-saving technologies and his leadership in AI innovation exemplify the type of visionary thinking that drives the success of early-stage ventures."

Event Details

  • Date: October 31, 2024
  • Time: 8:00 AM – 6:00 PM EDT
  • Location: Convene City View, 30 S 17th St, Philadelphia, PA

Accredited angel investors are encouraged to register for this exclusive event, where they can engage with the next wave of industry disruptors and gain key insights from one of healthcare’s leading innovators.

About Keiretsu Forum :

Keiretsu Forum is the world’s largest private equity angel investment network with 2000+ accredited investors in 35 North American and 23 International chapters, who have invested more than $1B in early-stage companies in the last 23 years.

The Keiretsu Forum portfolio features Entrepreneurs and Companies from Technology-(Internet, Software, Cyber Security, SaaS, Mobile Systems, IoT, etc.), Life Sciences-(Pharma, Medical Devices, Health IT, etc.), FinServ/FinTech, Consumer Products, Clean-Green Energy, Consumer Products, & more!

About Dr. Martin Gershon

Dr. Gershon's career has been marked by his pioneering efforts in healthcare and life sciences innovation. His role at Endeavor Venture Funds connects emerging companies with Fortune 500 partnerships, offering strategic growth solutions and regulatory expertise. Dr. Gershon has advised numerous organizations, including the White House Moonshot CancerX Accelerator, Goldman Sachs, and Bain Capital.

Dr. Gershon’s academic credentials are equally impressive, with advanced training in neuroscience, oncology, and immunology from Harvard, McGill, and Columbia. He has also served as an FDA attorney and has been honored as a Google Scholar in Entrepreneurship.

For media inquiries, please contact:

Cindi Sutera
AMS Communications
[email protected]
610-613-2773


GlobeNewsWire News

Recent Comments